A U.S. cannabis company, Curaleaf Holdings Inc., has expressed interest in acquiring Aurora Cannabis Inc., a company based in Edmonton. Aurora has responded by forming a special committee to review the unsolicited bid. The potential acquisition could lead to the creation of a combined cannabis entity operating in 17 countries globally.
Curaleaf, headquartered in Stamford, Conn., disclosed its intention to purchase all shares of Aurora after failed attempts to negotiate privately with Aurora’s leadership. Despite sending formal letters of intent on June 23 and July 7, Aurora’s board allegedly declined to engage in discussions with Curaleaf.
Curaleaf proposed paying Aurora shareholders $4 US per share in addition to $0.75 US cash for each Aurora share. Aurora confirmed receiving the letters from Curaleaf but disputed claims that it had rejected engagement with the offer. The Canadian company stated that its lead independent director had communicated with Curaleaf’s CEO as recently as July 24.
Aurora will establish a special committee of independent directors to evaluate the proposal’s alignment with stakeholders’ interests. The company emphasized that a deal is not guaranteed and that business operations will continue as usual. While Curaleaf’s bid is seen as positive, analysts caution that it undervalues Aurora’s long-term potential.
Curaleaf believes that merging the companies could create significant value by leveraging Curaleaf’s global distribution network with Aurora’s established international medical cannabis presence. The companies have collectively generated over $1.5 billion US in revenue in the past year, with Curaleaf anticipating annual cost synergies of at least $40 million US post-acquisition. The potential merger is viewed as mutually beneficial for both Curaleaf and Aurora shareholders, offering exposure to a diversified global platform and U.S. regulatory opportunities.
